Loading…

Cancer and Thrombotic Risk: The Platelet Paradigm

Hematologic malignancies and solid tumors increase the risk of venous and arterial thrombosis and contribute greatly to patient morbidity and mortality. Thrombosis occurs when the intricate balance of circulating antithrombotic and prothrombotic blood elements are disrupted. In recent years, the int...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in cardiovascular medicine 2017-11, Vol.4, p.67-67
Main Authors:	Lee, Elizabeth C, Cameron, Scott J
Format:	Article
Language:	English
Subjects:	antiocoagulation cancer progression Cardiovascular Medicine dysregulated platelets platelet activation platelet dysfunction thrombosis
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

cited_by	cdi_FETCH-LOGICAL-c459t-5bcd0a9887a2ee8d4f39e68cdcd3150013eaba27c0ae4c511128833ffccac5e53
cites	cdi_FETCH-LOGICAL-c459t-5bcd0a9887a2ee8d4f39e68cdcd3150013eaba27c0ae4c511128833ffccac5e53
container_end_page	67
container_issue
container_start_page	67
container_title	Frontiers in cardiovascular medicine
container_volume	4
creator	Lee, Elizabeth C Cameron, Scott J
description	Hematologic malignancies and solid tumors increase the risk of venous and arterial thrombosis and contribute greatly to patient morbidity and mortality. Thrombosis occurs when the intricate balance of circulating antithrombotic and prothrombotic blood elements are disrupted. In recent years, the interplay between paraneoplastic cells and platelets has become apparent, with a change in platelet phenotype causing dysregulated platelet activity. This review discusses mechanism of thrombosis in cancer, evidence for using drug therapy, and exciting research efforts to understand and hopefully control aberrant thrombotic events in patients with cancer.
doi_str_mv	10.3389/fcvm.2017.00067
format	article
fullrecord	<record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_177ccb87da694e5f899445df7a1cb80f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_177ccb87da694e5f899445df7a1cb80f</doaj_id><sourcerecordid>1967471873</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-5bcd0a9887a2ee8d4f39e68cdcd3150013eaba27c0ae4c511128833ffccac5e53</originalsourceid><addsrcrecordid>eNpVkc1LJDEQxYMoKqPnvS199DJj0kk6yR4WZFg_QFgRhb2F6qQyttvd0aRH2P_ejOOKnlK8vLw86kfIN0YXnGtzGtzLsKgpUwtKaaN2yGFdGzWnUv7Z_TQfkOOcH4uFSaFlo_fJQW1YIxgXh4QtYXSYKhh9dfeQ4tDGqXPVbZf__igCVjc9TNjjVN1AAt-thiOyF6DPePx-zsj9-a-75eX8-vfF1fLseu6ENNNcts5TMForqBG1F4EbbLTzznMmSxmO0EKtHAUUTjLGaq05D8E5cBIln5Grba6P8GifUjdA-mcjdPZNiGllIZWuPVqmlHOtVh4aI1AGbYwQ0gcFrMg0lKyf26yndTugdzhOCfovoV9vxu7BruKLLeuqN11n5OQ9IMXnNebJDl122PcwYlxny0yjhGJa8WI93VpdijknDB_fMGo33OyGm91ws2_cyovvn9t9-P9T4q9mwZRH</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1967471873</pqid></control><display><type>article</type><title>Cancer and Thrombotic Risk: The Platelet Paradigm</title><source>PubMed Central</source><creator>Lee, Elizabeth C ; Cameron, Scott J</creator><creatorcontrib>Lee, Elizabeth C ; Cameron, Scott J</creatorcontrib><description>Hematologic malignancies and solid tumors increase the risk of venous and arterial thrombosis and contribute greatly to patient morbidity and mortality. Thrombosis occurs when the intricate balance of circulating antithrombotic and prothrombotic blood elements are disrupted. In recent years, the interplay between paraneoplastic cells and platelets has become apparent, with a change in platelet phenotype causing dysregulated platelet activity. This review discusses mechanism of thrombosis in cancer, evidence for using drug therapy, and exciting research efforts to understand and hopefully control aberrant thrombotic events in patients with cancer.</description><identifier>ISSN: 2297-055X</identifier><identifier>EISSN: 2297-055X</identifier><identifier>DOI: 10.3389/fcvm.2017.00067</identifier><identifier>PMID: 29164134</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>antiocoagulation ; cancer progression ; Cardiovascular Medicine ; dysregulated platelets ; platelet activation ; platelet dysfunction ; thrombosis</subject><ispartof>Frontiers in cardiovascular medicine, 2017-11, Vol.4, p.67-67</ispartof><rights>Copyright © 2017 Lee and Cameron. 2017 Lee and Cameron</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-5bcd0a9887a2ee8d4f39e68cdcd3150013eaba27c0ae4c511128833ffccac5e53</citedby><cites>FETCH-LOGICAL-c459t-5bcd0a9887a2ee8d4f39e68cdcd3150013eaba27c0ae4c511128833ffccac5e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682001/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682001/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29164134$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Elizabeth C</creatorcontrib><creatorcontrib>Cameron, Scott J</creatorcontrib><title>Cancer and Thrombotic Risk: The Platelet Paradigm</title><title>Frontiers in cardiovascular medicine</title><addtitle>Front Cardiovasc Med</addtitle><description>Hematologic malignancies and solid tumors increase the risk of venous and arterial thrombosis and contribute greatly to patient morbidity and mortality. Thrombosis occurs when the intricate balance of circulating antithrombotic and prothrombotic blood elements are disrupted. In recent years, the interplay between paraneoplastic cells and platelets has become apparent, with a change in platelet phenotype causing dysregulated platelet activity. This review discusses mechanism of thrombosis in cancer, evidence for using drug therapy, and exciting research efforts to understand and hopefully control aberrant thrombotic events in patients with cancer.</description><subject>antiocoagulation</subject><subject>cancer progression</subject><subject>Cardiovascular Medicine</subject><subject>dysregulated platelets</subject><subject>platelet activation</subject><subject>platelet dysfunction</subject><subject>thrombosis</subject><issn>2297-055X</issn><issn>2297-055X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc1LJDEQxYMoKqPnvS199DJj0kk6yR4WZFg_QFgRhb2F6qQyttvd0aRH2P_ejOOKnlK8vLw86kfIN0YXnGtzGtzLsKgpUwtKaaN2yGFdGzWnUv7Z_TQfkOOcH4uFSaFlo_fJQW1YIxgXh4QtYXSYKhh9dfeQ4tDGqXPVbZf__igCVjc9TNjjVN1AAt-thiOyF6DPePx-zsj9-a-75eX8-vfF1fLseu6ENNNcts5TMForqBG1F4EbbLTzznMmSxmO0EKtHAUUTjLGaq05D8E5cBIln5Grba6P8GifUjdA-mcjdPZNiGllIZWuPVqmlHOtVh4aI1AGbYwQ0gcFrMg0lKyf26yndTugdzhOCfovoV9vxu7BruKLLeuqN11n5OQ9IMXnNebJDl122PcwYlxny0yjhGJa8WI93VpdijknDB_fMGo33OyGm91ws2_cyovvn9t9-P9T4q9mwZRH</recordid><startdate>20171107</startdate><enddate>20171107</enddate><creator>Lee, Elizabeth C</creator><creator>Cameron, Scott J</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20171107</creationdate><title>Cancer and Thrombotic Risk: The Platelet Paradigm</title><author>Lee, Elizabeth C ; Cameron, Scott J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-5bcd0a9887a2ee8d4f39e68cdcd3150013eaba27c0ae4c511128833ffccac5e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>antiocoagulation</topic><topic>cancer progression</topic><topic>Cardiovascular Medicine</topic><topic>dysregulated platelets</topic><topic>platelet activation</topic><topic>platelet dysfunction</topic><topic>thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Elizabeth C</creatorcontrib><creatorcontrib>Cameron, Scott J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in cardiovascular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Elizabeth C</au><au>Cameron, Scott J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer and Thrombotic Risk: The Platelet Paradigm</atitle><jtitle>Frontiers in cardiovascular medicine</jtitle><addtitle>Front Cardiovasc Med</addtitle><date>2017-11-07</date><risdate>2017</risdate><volume>4</volume><spage>67</spage><epage>67</epage><pages>67-67</pages><issn>2297-055X</issn><eissn>2297-055X</eissn><abstract>Hematologic malignancies and solid tumors increase the risk of venous and arterial thrombosis and contribute greatly to patient morbidity and mortality. Thrombosis occurs when the intricate balance of circulating antithrombotic and prothrombotic blood elements are disrupted. In recent years, the interplay between paraneoplastic cells and platelets has become apparent, with a change in platelet phenotype causing dysregulated platelet activity. This review discusses mechanism of thrombosis in cancer, evidence for using drug therapy, and exciting research efforts to understand and hopefully control aberrant thrombotic events in patients with cancer.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>29164134</pmid><doi>10.3389/fcvm.2017.00067</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 2297-055X
ispartof	Frontiers in cardiovascular medicine, 2017-11, Vol.4, p.67-67
issn	2297-055X 2297-055X
language	eng
recordid	cdi_doaj_primary_oai_doaj_org_article_177ccb87da694e5f899445df7a1cb80f
source	PubMed Central
subjects	antiocoagulation cancer progression Cardiovascular Medicine dysregulated platelets platelet activation platelet dysfunction thrombosis
title	Cancer and Thrombotic Risk: The Platelet Paradigm
url	http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A15%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20and%20Thrombotic%20Risk:%20The%20Platelet%20Paradigm&rft.jtitle=Frontiers%20in%20cardiovascular%20medicine&rft.au=Lee,%20Elizabeth%20C&rft.date=2017-11-07&rft.volume=4&rft.spage=67&rft.epage=67&rft.pages=67-67&rft.issn=2297-055X&rft.eissn=2297-055X&rft_id=info:doi/10.3389/fcvm.2017.00067&rft_dat=%3Cproquest_doaj_%3E1967471873%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-5bcd0a9887a2ee8d4f39e68cdcd3150013eaba27c0ae4c511128833ffccac5e53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1967471873&rft_id=info:pmid/29164134&rfr_iscdi=true